GlaxoSmithKline to acquire Genelabs Technologies to increase focus on novel small molecule therapies
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline [LSE/NYSE: GSK] and Genelabs Technologies, Inc. [NASDAQ: GNLB] have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (£35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSKâs effort to develop and deliver novel therapies against the hepatitis C virus (HCV).
AstraZeneca PLC Third Quarter and Nine Months Results 2008
- Details
- Category: AstraZeneca
AstraZeneca PLC has reported that sales in the third quarter increased by 3 percent at CER, or 9 percent on an as reported basis. Sales in the US were unchanged, as the $141 million decline in sales of Toprol-XL from generic competition was offset by 5 percent growth in the rest of the US business.
Novartis to acquire Nektar Therapeutics pulmonary business unit
- Details
- Category: Novartis
Novartis has strengthened its capabilities for developing medicines that can be delivered via the lungs through a definitive agreement to acquire the pulmonary drug delivery business unit of Nektar Therapeutics (NASDAQ: NKTR) for USD 115 million in cash.
European CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia
- Details
- Category: Boehringer Ingelheim
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a negative opinion on a Cymbalta® (duloxetine hydrochloride) application for the treatment of fibromyalgia.
Roche posts sustained double-digit sales growth for the first nine months of 2008
- Details
- Category: Roche
Sales by the Roche Group in the first nine months of 2008 increased by 6% in local currencies (-2% in Swiss francs; 13% in US dollars) to 33.3 billion Swiss francs. Excluding Tamiflu pandemic sales to governments and corporations, sales rose 10% (2% in Swiss francs; 17% in US dollars). The rise in the Swiss franc against most currencies, particularly against the US dollar, resulted in Swiss franc growth being eight percentage points lower than growth in local currencies.
Genzyme Reports Strong Third-Quarter Sales and Earnings Growth
- Details
- Category: Genzyme
Genzyme Corporation (NASDAQ: GENZ) has announced that third-quarter revenue rose 21 percent to $1.160 billion, compared with revenue of $960.2 million in the same period a year ago. The increase was driven by double-digit growth in every Genzyme business unit.
AstraZeneca Announces European SEROQUEL XR Submission
- Details
- Category: AstraZeneca
AstraZeneca has announced its submission of SEROQUEL XR (quetiapine fumarate extended release tablets) to European regulatory authorities seeking approval for both short-term and maintenance treatment of Generalised Anxiety Disorder (GAD).
More Pharma News ...
- Pfizer and UCB Announce Formation of New Company Cyclofluidic to Accelerate Drug Discovery Process
- GSKâs Emerging Markets strategy advances with acquisition in Egypt
- Pfizer Reaches Agreements in Principle to Resolve Litigation Involving Its NSAID Pain Medications
- Abbott Reports Strong Sales and Earnings Growth in Third Quarter
- GSK responds to NICE's second technology appraisal consultation document on the use of Tyverb
- European Journalists' Prize 2008 announced by Bayer HealthCare
- Early data show potential for imatinib to treat life-threatening form of pulmonary artery disease